Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy

J Pediatr Hematol Oncol. 2014 Mar;36(2):152-5. doi: 10.1097/MPH.0000000000000024.

Abstract

Nonpharmacologic, mind-body interventions are used to reduce anxiety in pediatric patients. Anti-ganglioside GD2 monoclonal antibody (anti-GD2 MoAb 3F8) therapy is the standard of care for high-risk neuroblastoma and pain is its major side effect. We performed a retrospective analysis of children undergoing anti-GD2 MoAb 3F8 treatment who received guided meditation. Meditation involved concentrating on the repetition of rhythmic, melodic sounds purported to slow breathing and induce a relaxation response. A total of 71% patients completed a session at first (n=19) or second attempt (n=5). Patients received fewer analgesic doses to manage anti-GD2 MoAb 3F8-induced pain when participating in meditation (n=17, mean=-0.4 dose, P<0.01). Mantram meditation is a feasible outpatient intervention associated with reduced analgesic requirements.

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Agents / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • Gangliosides / antagonists & inhibitors
  • Humans
  • Male
  • Meditation* / methods
  • Meditation* / psychology
  • Neuroblastoma / drug therapy*
  • Pain / etiology
  • Pain / prevention & control*
  • Pain / psychology*
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Gangliosides
  • ganglioside, GD2